📣 VC round data is live. Check it out!
- Public Comps
- BrainsWay
BrainsWay Valuation Multiples
Discover BrainsWay's revenue and EBITDA valuation multiples and investment history, alongside public comparables like SD Biosensor, Mesa Laboratories, Beta Bionics, SI-BONE and more.
BrainsWay Overview
About BrainsWay
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Founded
2006
HQ

Employees
120
Website
Financials (LTM)
EV
$540M
Valuation Multiples
Start free trialBrainsWay Financials
BrainsWay reported last 12-month revenue of $59M and EBITDA of $9M.
In the same LTM period, BrainsWay generated $44M in gross profit, $9M in EBITDA, and $10M in net income.
Revenue (LTM)
BrainsWay P&L
In the most recent fiscal year, BrainsWay reported revenue of $52M and EBITDA of $10M.
BrainsWay is profitable as of last fiscal year, with gross margin of 75%, EBITDA margin of 19%, and net margin of 15%.
Financial data powered by Morningstar, Inc.
BrainsWay Stock Performance
BrainsWay has current market cap of $593M, and enterprise value of $540M.
Market Cap Evolution
BrainsWay's stock price is $14.80.
BrainsWay share price decreased by 10.0% in the last 30 days, and increased by 12.3% in the last year.
BrainsWay has an EPS (earnings per share) of $0.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $540M | $593M | -2.8% | -10.0% | 8.5% | 12.3% | $0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBrainsWay Valuation Multiples
BrainsWay trades at 9.2x EV/Revenue multiple, and 57.3x EV/EBITDA.
EV / Revenue (LTM)
BrainsWay Financial Valuation Multiples
As of June 4, 2026, BrainsWay has market cap of $593M and EV of $540M.
BrainsWay has a P/E ratio of 62.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BrainsWay Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


BrainsWay Margins & Growth Rates
BrainsWay grew revenue by 29% and EBITDA by 29% in the last fiscal year.
In the most recent fiscal year, BrainsWay reported gross margin of 75%, EBITDA margin of 19%, and net margin of 15%.
BrainsWay Margins
BrainsWay Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
BrainsWay Operational KPIs
BrainsWay's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
BrainsWay's Rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BrainsWay's Rule of X is 90% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
BrainsWay Competitors
BrainsWay competitors include SD Biosensor, Mesa Laboratories, Beta Bionics, SI-BONE, Japan Lifeline, NeuroPace, Sofwave Medical, Synektik, Advanced Medical Solutions Group and Tactile Medical.
Most BrainsWay public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.0x | - | (1.0x) | - | |||
| 3.1x | 3.0x | 17.5x | 11.6x | |||
| 3.8x | 3.3x | (7.1x) | (5.9x) | |||
| 2.6x | 2.4x | 58.3x | 51.0x | |||
| 1.4x | 1.3x | 5.8x | 5.6x | |||
| 5.7x | 5.7x | (114.3x) | (86.6x) | |||
| 6.0x | - | 68.7x | - | |||
| 2.8x | 2.5x | 11.3x | 9.8x | |||
This data is available for Pro users. Sign up to see all BrainsWay competitors and their valuation data. Start Free Trial | ||||||
Investments by BrainsWay
BrainsWay has invested in 6 companies to date.
Latest investment by BrainsWay was on May 17th 2026. BrainsWay invested in Hopemark Health in their $2M Strategic investment round (EV/Revenue multiple available to Pro users).
Latest Investments by BrainsWay
| Description | Hopemark Health is a psychiatric clinic that offers mental health care, ketamine therapy, and genetic testing services. | Neurolief is an Israel-headquartered neuromodulation company treating mental health and neurological disorders with non-invasive devices. Its platform delivers multi-channel electrical stimulation to key cranial neural pathways simultaneously, modulating brain areas for mood regulation and pain relief. Targeting depression, anxiety, and migraines, the wearable system offers home-based therapy sessions. Neurolief employs neuroscience veterans to refine pulse patterns based on clinical feedback from European and US trials. | BrainStim Health manages clinics delivering neuroplasticity treatments including TMS and ketamine for mental health conditions. | Heading Health is a mental health platform utilizing technology for personalized treatments including Spravato nasal spray, transcranial magnetic stimulation, telepsychiatry sessions, and intramuscular ketamine infusions. The service operates virtual clinics in multiple US states to expand access to evidence-based therapies. | |
| HQ Country | |||||
| HQ City | Oak Brook, IL | Netanya | - | Austin, TX | |
| Deal Date | 17 May 2026 | 25 Mar 2026 | 19 Feb 2026 | 27 Oct 2025 | |
| Round | Strategic investment | Undisclosed stage | Strategic investment | Strategic investment | |
| Raised | $2M | $6M | $1M | $2M | |
| Investors | BrainsWay | BrainsWay | BrainsWay | BrainsWay | |
| Valuation | $3M | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all BrainsWay investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BrainsWay
| When was BrainsWay founded? | BrainsWay was founded in 2006. |
| Where is BrainsWay headquartered? | BrainsWay is headquartered in Israel. |
| How many employees does BrainsWay have? | As of today, BrainsWay has over 120 employees. |
| Who is the CEO of BrainsWay? | BrainsWay's CEO is Hadar Levy. |
| Is BrainsWay publicly listed? | Yes, BrainsWay is a public company listed on Nasdaq. |
| What is the stock symbol of BrainsWay? | BrainsWay trades under BWAY ticker. |
| When did BrainsWay go public? | BrainsWay went public in 2019. |
| Who are competitors of BrainsWay? | BrainsWay main competitors include SD Biosensor, Mesa Laboratories, Beta Bionics, SI-BONE, Japan Lifeline, NeuroPace, Sofwave Medical, Synektik, Advanced Medical Solutions Group, Tactile Medical. |
| What is the current market cap of BrainsWay? | BrainsWay's current market cap is $593M. |
| What is the current revenue of BrainsWay? | BrainsWay's last 12 months revenue is $59M. |
| What is the current revenue growth of BrainsWay? | BrainsWay revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of BrainsWay? | Current revenue multiple of BrainsWay is 9.2x. |
| What is the current EBITDA of BrainsWay? | BrainsWay's last 12 months EBITDA is $9M. |
| What is BrainsWay's EBITDA margin? | BrainsWay's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of BrainsWay? | Current EBITDA multiple of BrainsWay is 57.3x. |
| How many companies BrainsWay has acquired to date? | BrainsWay hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies BrainsWay has invested to date? | As of June 2026, BrainsWay has invested in 6 companies. |
| What was the last BrainsWay investment? | On 17th May 2026 BrainsWay invested in Hopemark Health, participating in a $2M Strategic investment round at $3M valuation. |
| In what companies BrainsWay invested in? | BrainsWay invested in Neurolief, Stella Mental Health, Axis Integrated Mental Health, Hopemark Health, Heading Health, and Brainstim Health. |
See public comps similar to BrainsWay
Lists including BrainsWay
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


